Citations

Clear

904 citation(s) found for "Gordon, S".

Penile Replantation: A Retrospective Analysis of Outcomes and Complications
Morrison, Shane D. , Shakir, Afaaf , Vyas, Krishna S. , Remington, Austin C., Mogni, Benjamin, Wilson, Stelios C., Grant, David , Cho, Daniel , Rahnemai‐Azar, Amir A., Lee, Gordon , Mardini, Samir , Friedrich, Jeffrey B.

Mayo Clinic

Journal of Reconstructive Microsurgery | December 22, 2016 | Volume: 33 | Issue: 04 | Pages: 227-232

10.1055/s-0036-1597567 | PMID 28002849 Get It

Towards the reduction of injury and illness in athletes: defining our research priorities
Finch, Caroline F. , Hewett, Timothy E. , Junge, Astrid , MacAuley, Domhnall, Matheson, Gordon O., McCrory, Paul , Verhagen, Evert , Hewett, Timothy, Bahr, Roald , Drezner, Jonathan A. , Dvořák, Jiří , Engebretsen, Lars , Khan, Karim M. , Verhagen, Evert

Mayo Clinic

British Journal of Sports Medicine | December 21, 2016 | Volume: 51 | Issue: 16 | Pages: 1178-1182

10.1136/bjsports-2016-097042 | PMID 28003237 Get It

Histone H4 Methyltransferase Suv420h2 Maintains Fidelity of Osteoblast Differentiation
Khani, Farzaneh , Thaler, Roman , Paradise, Christopher R. , Deyle, David R. , Julio, Marianne Kruijthof‐de, Galindo, Mario , Gordon, Jonathan A. R., Dudakovic, Amel , Wijnen, André J. van , van Wijnen, Andre J, Stein, Gary S. , van Wijnen, Andre J , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Biochemistry | November 10, 2016 | Volume: 118 | Issue: 5 | Pages: 1262-1272

10.1002/jcb.25787 | PMID 27862226 Get It

ABSTRACTOsteogenic lineage commitment and progression is controlled by multiple signaling pathways (e.g., WNT, BMP, FGF) that converge on bone‐related transcription factors. Access of osteogenic transcription factors to chromatin is controlled by epigenetic regulators that generate post‐translational modifications of histones (“histone code”), as well as read, edit and/or erase these modifications. Our understanding of the biological role of epigenetic regulators in osteoblast differentiation remains limited. Therefore, we performed next‐generation RNA sequencing (RNA‐seq) and established which chromatin‐related proteins are robustly expressed in mouse bone tissues (e.g., fracture callus, calvarial bone). These studies also revealed that cells with increased osteogenic potential have higher levels of the H4K20 methyl transferase Suv420h2 compared to other methyl transferases (e.g., Suv39h1, Suv39h2, Suv420h1, Ezh1, Ezh2). We find that all six epigenetic regulators are transiently expressed at different stages of osteoblast differentiation in culture, with maximal mRNAs levels of Suv39h1 and Suv39h2 (at day 3) preceding maximal expression of Suv420h1 and Suv420h2 (at day 7) and developmental stages that reflect, respectively, early and later collagen matrix deposition. Loss of function analysis of Suv420h2 by siRNA depletion shows loss of H4K20 methylation and decreased expression of bone biomarkers (e.g., alkaline phosphatase/Alpl) and osteogenic transcription factors (e.g., Sp7/Osterix). Furthermore, Suv420h2 is required for matrix mineralization during osteoblast differentiation. We conclude that Suv420h2 controls the H4K20 methylome of osteoblasts and is critical for normal progression of osteoblastogenesis. J. Cell. Biochem. 118: 1262–1272, 2017. © 2016 Wiley Periodicals, Inc.
Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study
Laffey, John G. , Pham, Tài , Madotto, Fabiana , Brochard, Laurent , Esteban, Andres, Gattinoni, Luciano , Bumbaširević, Vesna, Piquilloud, Lise , Haren, Frank van , Larsson, Anders, McAuley, Daniel F. , Arabi, Yaseen M. , Ranieri, Marco, Antonelli, Massimo , Rubenfeld, Gordon D., Wrigge, Hermann , Slutsky, Arthur S. , Schultz, Marcus J. , Bajwa, Ednan K. , Ferguson, Niall D. , Frendl, György , Brown, Samuel M. , Terzi, Nicolas , Brazzi, Luca , Montini, Luca , Tomescu, Dana , Lanspa, Michael J. , Almekhlafi, Ghaleb A. , Cortegiani, Andrea , Fusari, Maurizio , González-Castro, A. , Parotto, Matteo , Sánchez‐Hurtado, Luis Alejandro , Spadaro, Savino , Szakmány, Tamás , Zani, Gianluca , Bihari, Shailesh , Laffey, John G , Bellani, Giacomo , Fan, Eddy , Esteban, Andres, Bauer, Philippe R. , Thompson, Bruce , Pesenti, Antonio Maria , Schultz, Marcus J , Arabi, Yaseen M , Beitler, Jeremy R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 18, 2016 | Volume: 195 | Issue: 1 | Pages: 67-77

10.1164/rccm.201606-1306oc | PMID 27753501 Get It

Abstract Rationale Noninvasive ventilation (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS). The evidence supporting NIV use in patients with ARDS remains relatively sparse. Objectives To determine whether, during NIV, the categorization of ARDS severity based on the PaO2/FiO2 Berlin criteria is useful. Methods The LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of patients with ARDS. This substudy examines the current practice of NIV use in ARDS, the utility of the PaO2/FiO2 ratio in classifying patients receiving NIV, and the impact of NIV on outcome. Measurements and Main Results Of 2,813 patients with ARDS, 436 (15.5%) were managed with NIV on Days 1 and 2 following fulfillment of diagnostic criteria. Classification of ARDS severity based on PaO2/FiO2 ratio was associated with an increase in intensity of ventilatory support, NIV failure, and intensive care unit (ICU) mortality. NIV failure occurred in 22.2% of mild, 42.3% of moderate, and 47.1% of patients with severe ARDS. Hospital mortality in patients with NIV success and failure was 16.1% and 45.4%, respectively. NIV use was independently associated with increased ICU (hazard ratio, 1.446 [95% confidence interval, 1.159–1.805]), but not hospital, mortality. In a propensity matched analysis, ICU mortality was higher in NIV than invasively ventilated patients with a PaO2/FiO2 lower than 150 mm Hg. Conclusions NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV seems to be associated with higher ICU mortality in patients with a PaO2/FiO2 lower than 150 mm Hg. Clinical trial registered with www.clinicaltrials.gov (NCT 02010073).
F4‐02‐04: The Alzheimer's Prevention Initiative (API) Program: Genetic Testing and Disclosure Strategies
Karlawish, Jason , Bradbury, Angela R. , Wood, Elisabeth, Roberts, J. Scott , Patrick‐Miller, Linda , Blacker, Deborah, Caselli, Richard J. , Marchant, Gary E. , Zallen, Doris T. , Langlois, Carolyn, Walsh, Trisha, Gordon, David , Reiman, Eric M. , Tariot, Pierre N. , Langbaum, Jessica B. S. , Wood, Elisabeth McCarty , Kim, Scott Y. H. , Patrick‐Miller, Linda , Blacker, Deborah

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2016.06.595 Get It

Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort
Leister, Erin, Coryell, Jason , Nickels, Katherine , Ryan, Nicole, Juarez‐Colunga, Elizabeth , Gaillard, William D. , Mytinger, John R. , Berg, Anne T. , Millichap, J Gordon , Nordli, Douglas R. , Joshi, Sucheta M. , Shellhaas, Renée A. , Loddenkemper, Tobias , Dlugos, Dennis , Sullivan, Joseph , Hartman, Adam L. , Kossoff, Eric H. , Grinspan, Zachary M. , Hamikawa, Lorie, Wusthoff, Courtney J. , Novotny, Edward J. , Yozawitz, Elissa , Millichap, John , Knupp, Kelly G. , Wirrell, Elaine , Shellhaas, Renée A , Novotny, Edward J , Gaillard, William D , Loddenkemper, Tobias , Yozawitz, Elissa G , Berg, Anne T , Grinspan, Zachary , Nickels, Katherine C , Coryell, Jason , Wusthoff, Courtney J

Mayo Clinic

Epilepsia | September 12, 2016 | Volume: 57 | Issue: 11 | Pages: 1834-1842

10.1111/epi.13557 | PMID 27615012 Get It

Summary Objective Infantile spasms ( IS ) represent a severe epileptic encephalopathy presenting in the first 2 years of life. Recommended first‐line therapies (hormonal therapy or vigabatrin) often fail. We evaluated response to second treatment for IS in children in whom the initial therapy failed to produce both clinical remission and electrographic resolution of hypsarhythmia and whether time to treatment was related to outcome. Methods The National Infantile Spasms Consortium established a multicenter, prospective database enrolling infants with new diagnosis of IS. Children were considered nonresponders to first treatment if there was no clinical remission or persistence of hypsarhythmia. Treatment was evaluated as hormonal therapy (adrenocorticotropic hormone [ ACTH ] or oral corticosteroids), vigabatrin, or “other.” Standard treatments (hormonal and vigabatrin) were compared to all other nonstandard treatments. We compared response rates using chi‐square tests and multivariable logistic regression models. Results One hundred eighteen infants were included from 19 centers. Overall response rate to a second treatment was 37% (n = 44). Children who received standard medications with differing mechanisms for first and second treatment had higher response rates than other sequences (27/49 [55%] vs. 17/69 [25%], p < 0.001). Children receiving first treatment within 4 weeks of IS onset had a higher response rate to second treatment than those initially treated later (36/82 [44%] vs. 8/34 [24%], p = 0.040). Significance Greater than one third of children with IS will respond to a second medication. Choosing a standard medication ( ACTH , oral corticosteroids, or vigabatrin) that has a different mechanism of action appears to be more effective. Rapid initial treatment increases the likelihood of response to the second treatment.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Cheson, Bruce D. , Ansell, Stephen M. , Schwartz, Larry, Advani, Ranjana H. , Jacene, Heather A. , Hoos, Axel , Barrington, Sally F. , Armand, Philippe , Schwartz, Larry, Gordon, Leo I. , Advani, Ranjana H

Mayo Clinic

Blood | August 30, 2016 | Volume: 128 | Issue: 21 | Pages: 2489-2496

10.1182/blood-2016-05-718528 | PMID 27574190 Get It

AbstractUniformly adopted response criteria are essential for assessment of therapies incorporating conventional chemotherapy and chemoimmunotherapy regimens. Recently, immunomodulatory agents, such as immune checkpoint inhibitors, have demonstrated impressive activity in a broad range of lymphoma histologies. However, these agents may be associated with clinical and imaging findings during treatment suggestive of progressive disease (PD) despite evidence of clinical benefit (eg, tumor flare or pseudo-progression). Considering this finding as PD could lead to patients being prematurely removed from a treatment from which they actually stand to benefit. This phenomenon has been well described with checkpoint blockade therapy in solid tumors and anecdotally seen in lymphoma as well. To address this issue in the context of lymphoma immunomodulatory therapy, a workshop was convened to provide provisional recommendations to modify current response criteria in patients receiving these and future agents in clinical trials. The term “indeterminate response” was introduced to identify such lesions until confirmed as flare/pseudo-progression or true PD by either biopsy or subsequent imaging.
Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
Shankar, Sudha S. , Raymond, Ralph, Staten, Myrlene A. , Calle, Roberto A. , Bergman, Richard N. , Cao, Charlie, Man, Chiara Dalla , Deeg, Mark A. , Dong, Jennifer , Polidori, David , Robertson, R. Paul , Ruetten, Hartmut, Stefanovski, Darko , Vassileva, Maria T. , Weir, Gordon C. , Vella, Adrian , Chen, Danny, Cobelli, Claudio , Lee, Douglas S. , Fryburg, David A. , Dalla Man, Chiara

Mayo Clinic

Diabetes Care | July 13, 2016 | Volume: 39 | Issue: 9 | Pages: 1602-1613

10.2337/dc15-0931 | PMID 27407117 Get It

OBJECTIVE Standardized, reproducible, and feasible quantification of β-cell function (BCF) is necessary for the evaluation of interventions to improve insulin secretion and important for comparison across studies. We therefore characterized the responses to, and reproducibility of, standardized methods of in vivo BCF across different glucose tolerance states. RESEARCH DESIGN AND METHODS Participants classified as having normal glucose tolerance (NGT; n = 23), prediabetes (PDM; n = 17), and type 2 diabetes mellitus (T2DM; n = 22) underwent two standardized mixed-meal tolerance tests (MMTT) and two standardized arginine stimulation tests (AST) in a test-retest paradigm and one frequently sampled intravenous glucose tolerance test (FSIGT). RESULTS From the MMTT, insulin secretion in T2DM was &gt;86% lower compared with NGT or PDM (P &lt; 0.001). Insulin sensitivity (Si) decreased from NGT to PDM (∼50%) to T2DM (93% lower [P &lt; 0.001]). In the AST, insulin secretory response to arginine at basal glucose and during hyperglycemia was lower in T2DM compared with NGT and PDM (&gt;58%; all P &lt; 0.001). FSIGT showed decreases in both insulin secretion and Si across populations (P &lt; 0.001), although Si did not differ significantly between PDM and T2DM populations. Reproducibility was generally good for the MMTT, with intraclass correlation coefficients (ICCs) ranging from ∼0.3 to ∼0.8 depending on population and variable. Reproducibility for the AST was very good, with ICC values &gt;0.8 across all variables and populations. CONCLUSIONS Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use.